Idexx Laboratories

IDXX

Market cap $60.1B

Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.

IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.

Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

The steep increase in pet healthcare costs have doubled over the past five years, according to NPR.

Baron Asset Fund underperformed for a second consecutive quarter as U.S. equities continued their strong rally from the market lows reached on April 8. From a sector perspective, stock selection in IT and Communication Services was responsible for about three-quarters of the underperformance in the period. Stock selection in Consumer Discretionary, Financials, and Industrials hampered relative results.

No single month beats November for S&P 500 stock market performance. And a handful of stocks are already taking off.

Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.

Idexx Laboratories (IDXX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IDXX broke through the 20-day moving average, which suggests a short-term bullish trend.